Pacira's long-acting pain drug advancing

En route to a potential FDA approval next month, Pacira Pharmaceuticals ($PCRX) reports data from previous trials of its lead drug Exparel for postsurgical pain. In patients who had surgery to enlarge their breasts and took the drug, there were no signs of ill effects in healing or breast appearance 13 months and two years after their surgeries. The data were presented on Sept. 24 at the annual American Society of Plastic Surgeons meeting in Denver. The FDA is expected to complete its review of the drug for postsurgical pain and decide whether to give it a market green light by Oct. 28. Exparel consists of the approved drug bupivacaine and is encased in liposome particles that enable the active ingredient to be released gradually. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.